Cancer Patients Faced Higher Infection Risks in Study
Researchers linked triple immunosuppressive therapy to increased infection rates in cancer patients.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Do you trust the safety of multi-drug immunosuppressive treatments when managing serious autoimmune reactions?
Mass General Brigham investigators found that cancer patients receiving multiple immunosuppressive therapies for treatment complications face a heightened risk of infection. Over half of patients treated with a combination of steroids and two non-steroidal therapies developed infections.
Why it matters
The study highlights the delicate balance between managing autoimmune complications from cancer immunotherapy and protecting patients from life-threatening infections. These findings suggest a need for improved screening strategies to protect vulnerable patients during treatment.
Researchers studied 20,930 patients, identifying 142 individuals who received steroids plus two non-steroidal immunosuppressive therapies. Fifty-two percent of this triple-therapy group experienced infections, with nearly half of those cases being severe or fatal.
The players
Mass General Brigham
This is an integrated academic health care system based in Massachusetts that manages research and clinical operations across multiple hospitals.
The details
Researchers analyzed patient records to characterize infection risk following the use of immune checkpoint inhibitors, which can cause severe autoimmune complications. Data showed that patients aged 65 and older were particularly susceptible to opportunistic infections, with cytomegalovirus being the most common cause identified.
Timeline
June 2011 marked the start of the patient cohort study period.
February 2024 marked the end of the patient cohort study period.
Study findings were published on September 24, 2026.
Health Landscape
This study follows a pattern of monitoring emerging clinical complications set by the Mass General Brigham Cancer Institute's immune checkpoint inhibitor therapy protocols. It underscores the ongoing evolution of medical science as clinicians refine ways to manage the complex, systemic side effects of modern cancer treatments.
Patients undergoing immunotherapy should discuss their specific immunosuppression regimen and potential infection risks with their oncology team. Individuals aged 65 and older may need closer monitoring due to their higher susceptibility to opportunistic infections during treatment.
The takeaway
Clinicians must carefully weigh the necessity of aggressive immunosuppression against the significant danger of secondary infections in cancer patients. Patients and providers should prioritize early screening and vigilance, particularly for those receiving multiple concurrent therapies.
Further reading
For more information on the latest clinical findings, visit the Cancer section.
More information
Review the full findings in the journal article publication.
Live Poll
Do you trust the safety of multi-drug immunosuppressive treatments when managing serious autoimmune reactions?
